melflufen

01/01/2022 - "Clinical trials including melflufen in relapsed refractory multiple myeloma and trials related to safety and clinical pharmacology were included. "
04/04/2016 - "Melflufen is currently being evaluated in a clinical phase I/II trial in relapsed or relapsed and refractory multiple myeloma. "
08/01/2022 - "Melphalan flufenamide for relapsed/refractory multiple myeloma."
04/01/2022 - "Melflufen for the treatment of multiple myeloma."
01/01/2022 - "Growth Response and Differentiation of Bone Marrow-Derived Mesenchymal Stem/Stromal Cells in the Presence of Novel Multiple Myeloma Drug Melflufen."

01/01/2020 - "Finally, Melflufen displayed anti-tumor growth and anti-metastatic effects in vivo. "
04/04/2016 - "Cytotoxicity of melflufen was assayed in lymphoma cell lines and in primary tumor cells with the Fluorometric Microculture Cytotoxicity Assay and cell cycle analyses was performed in two of the cell lines. "
01/01/2020 - "Compared to the commonly used anti-cancer drug doxorubicin, melflufen was significantly more effective in reducing cell viability in vitro while it showed comparable effects in vivo. "
04/01/2020 - "Melflufen is a novel peptide-drug conjugate that rapidly delivers a cytotoxic payload into tumor cells. "
12/01/2015 - "In conclusion, melflufen can safely be given to cancer patients, and the toxicity profile was as expected for alkylating agents; RPTD is 50 mg Q3W. "

01/24/2017 - "The novel aminopeptidase potentiated alkylating agent melflufen, was evaluated for activity in acute myeloid leukemia in a range of in vitro models, as well as in a patient derived xenograft study. "
01/24/2017 - "In vitro and in vivo anti-leukemic activity of the peptidase-potentiated alkylator melflufen in acute myeloid leukemia."

09/13/2016 - "In addition, an intra- and subperitoneal xenograft model showed activity of intraperitoneal administered melflufen for peritoneal carcinomatosis, with minimal side effects and modest systemic exposure. "
09/13/2016 - "In conclusion, results from this study support further investigations of melflufen for the treatment of peritoneal carcinomatosis from ovarian cancer, both for intravenous and intraperitoneal administration."
09/13/2016 - "The pharmacological and physiochemical properties of melflufen, a peptidase potentiated alkylator, raised the hypothesis that this drug could be useful in ovarian cancer and particularily against peritoneal carcinomatosis. "

09/13/2016 - "In this study the preclinical effects of melflufen were investigated in different ovarian cancer models. "
09/13/2016 - "Preclinical activity of melflufen (J1) in ovarian cancer."
09/13/2016 - "In conclusion, results from this study support further investigations of melflufen for the treatment of peritoneal carcinomatosis from ovarian cancer, both for intravenous and intraperitoneal administration."
09/13/2016 - "Melflufen was active against ovarian cancer cell lines, primary cultures of patient-derived ovarian cancer cells, and inhibited the growth of subcutaneous A2780 ovarian cancer xenografts alone and when combined with gemcitabine or liposomal doxorubicin when administered intravenously. "
09/13/2016 - "The pharmacological and physiochemical properties of melflufen, a peptidase potentiated alkylator, raised the hypothesis that this drug could be useful in ovarian cancer and particularily against peritoneal carcinomatosis. "